The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects.

Feasibility and Advantages of PPAR-Targeting PROTACs The design of PROTACs targeting PPARs presents a unique opportunity to overcome the challenges associated with PPAR-targeted cancer therapies.

Two novel PPAR agonists, elafibranor and seladelpar, are being studied as second-line agents for the treatment of UDCA-resistant PBC.

Keisuke Yamamoto Tomohiro Tamura Rina Nakamura Shintaro Hosoe Masahiro Matsubara Keiko Nagata Hiroshi Kodaira Takeshi Uemori Yuichi Takahashi Michihiko Suzuki Jun-ichi Saito Kimihisa Ueno Satoshi ...

There is increasing evidence indicating that activation of peroxisome proliferator-activated receptor gamma (PPARγ) by its ligands can inhibit the growth of thyroid cancer, likely via multi-mechanisms ...

The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands. Biochem.

ABSTRACT: Background and Objectives: Peroxisome proliferator-activated receptor-g (PPAR-g) is a nuclear receptor whose activation regulates inflammation and fibrosis in various organs. We aimed to ...

Dual or pan PPAR ligands stimulate two or more isoforms of PPAR and thereby reduce insulin resistance and prevent short- and long-term complications of diabetes including micro-and macroangiopathy and ...

The Peroxisome Proliferator–Activated Receptor (PPAR)- γ Antagonist 2-Chloro-5-Nitro-N-Phenylbenzamide (GW9662) Triggers Perilipin 2 Expression via PPAR δ and Induces Lipogenesis and Triglyceride ...

The nuclear receptor retinoid X receptor‐α (RXR‐α)–peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) heterodimer was recently reported to have a crucial function in mediating the deleterious ...

Troglitazone-suppressed stomach cancer via activation of PPAR-gamma, and stomach cancer was suppressed by apoptosis mediated by PPAR-gamma ligands. After we confirmed the appearance of PPAR-gamma ...